DPYD Genotyping Recommendations
DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium
This course contains the webinar, a handout, and continuing education credit (CME and CMLE)
Description:
This webinar is based on new consensus recommendations from the Association for Molecular Pathology to aid in the design and validation of clinical DPYD genotyping assays, promote standardization of testing across different laboratories, and improve patient care. The AMP Clinical Practice Committee’s Pharmacogenomics (PGx) Working Group with representation from American College of Medical Genetics and Genomics (ACMG), Clinical Pharmacogenetics Implementation Consortium (CPIC), College of American Pathologists (CAP), Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy (ESPT), Pharmacogenomics Knowledgebase (PharmGKB®), and Pharmacogene Variation Consortium (PharmVar) has developed a series of recommendations to help standardize clinical testing for frequently used genotyping assays. The new DPYD report builds on the earlier clinical genotyping recommendations for CYP3A4/CYP3A5, TPMT/NUDT15, CYP2D6, genes important for warfarin testing, CYP2C9, and CYP2C19 and should be implemented along with other relevant clinical guidelines. The AMP PGx Working Group used a two-tier categorization of variants recommended for inclusion, as with previous clinical PGx genotyping assay recommendations.
Learning Objectives:
- Review DPYD pharmacogenetics and highlight the importance of standardization of clinical pharmacogenetics and its implications to patient care.
- Review the AMP Pharmacogenomics (PGx) Working Group ‘Tier’ system of pharmacogenetics sequence variants/alleles recommendation.
- Explain the key attributes of Tier 1 and Tier 2 recommended alleles for DPYD genotyping.
Speaker
Reynold Ly, PhD
Nationwide Children’s Hospital
Moderator
Ann M. Moyer, MD, PhD
Mayo Clinic
Duration: 1 Hour
Level of Instruction: Basic
Live Webinar: October 15, 2024
Date Recorded: August 7, 2024
Planned and coordinated by the Clinical Practice Committee and Training and Education Committee
Continuing Education Credit Information
CME credit: 1.0
CMLE credit: 1.0
Last day to claim credit: March 20, 2027
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Note: Members of AMP can access this webinar at no cost. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.